Congratulations to Social Work Lecturer Dr. Orlanda Harvey on the acceptance of a paper by the journal Drugs: Education, Prevention & Policy. This latest academic paper ‘Libido as a motivator for starting and restarting non-prescribed anabolic androgenic steroid use among men: a mixed-methods study’ [1] is based on her Ph.D. research. Previous papers associated with her thesis covered aspects of non-prescribed anabolic androgenic steroid use [2-3] as well as her wider Ph.D. journey [4].
References:
-
- Harvey, O., Parrish, M., van Teijlingen, E, Trenoweth, S. (2021) Libido as a reason to use non-prescribed Anabolic Androgenic Steroids, Drugs: Education, Prevention & Policy (accepted).
- Harvey, O., Keen, S., Parrish, M., van Teijlingen, E. (2019) Support for people who use Anabolic Androgenic Steroids: A Systematic Literature Review into what they want and what they access. BMC Public Health 19: 1024 https://doi.org/10.1186/s12889-019-7288-x https://rdcu.be/bMFon
- Harvey, O., Parrish, M., van Teijlingen, E., Trenoweth, S. (2020) Support for non-prescribed Anabolic Androgenic Steroids users: A qualitative exploration of their needs Drugs: Education, Prevention & Policy 27:5, 377-386. doi 10.1080/09687637.2019.1705763
- Spacey, A., Harvey, O., Casey, C. (2020) Postgraduate researchers’ experiences of accessing participants via gatekeepers: ‘wading through treacle!’ Journal of Further and Higher Education 2: 1-18.
























































Register now to attend the 17th Annual Postgraduate Research Conference – Wednesday 3 December 2025
Portrait Concert featuring BU academic at L’Espace du Son Festival 2025, Brussels
From Clinical Applications to Neuro-Inspired Computation
ECR Funding Open Call: Research Culture & Community Grant – Apply Now
MSCA Postdoctoral Fellowships 2025 Call
ERC Advanced Grant 2025 Webinar
Horizon Europe Work Programme 2025 Published
Horizon Europe 2025 Work Programme pre-Published
Update on UKRO services
European research project exploring use of ‘virtual twins’ to better manage metabolic associated fatty liver disease